Kubilay Tolunay, P.; Kurt İnci, B.; Usta, Ş.; Topkaç, A.; Karabuğa, B.; Aydemir, E.; Öner, İ.; Akay Hacan, B.; Ateş, Ö.; Karaçin, C.;
et al. Timing of Dose Reductions and Survival Outcomes in Metastatic Breast Cancer Patients Treated with Cyclin-Dependent Kinase 4/6 Inhibitors. Curr. Oncol. 2024, 31, 7426-7436.
https://doi.org/10.3390/curroncol31120548
AMA Style
Kubilay Tolunay P, Kurt İnci B, Usta Ş, Topkaç A, Karabuğa B, Aydemir E, Öner İ, Akay Hacan B, Ateş Ö, Karaçin C,
et al. Timing of Dose Reductions and Survival Outcomes in Metastatic Breast Cancer Patients Treated with Cyclin-Dependent Kinase 4/6 Inhibitors. Current Oncology. 2024; 31(12):7426-7436.
https://doi.org/10.3390/curroncol31120548
Chicago/Turabian Style
Kubilay Tolunay, Pınar, Bediz Kurt İnci, Şura Usta, Ali Topkaç, Berkan Karabuğa, Ergin Aydemir, İrem Öner, Büşra Akay Hacan, Öztürk Ateş, Cengiz Karaçin,
and et al. 2024. "Timing of Dose Reductions and Survival Outcomes in Metastatic Breast Cancer Patients Treated with Cyclin-Dependent Kinase 4/6 Inhibitors" Current Oncology 31, no. 12: 7426-7436.
https://doi.org/10.3390/curroncol31120548
APA Style
Kubilay Tolunay, P., Kurt İnci, B., Usta, Ş., Topkaç, A., Karabuğa, B., Aydemir, E., Öner, İ., Akay Hacan, B., Ateş, Ö., Karaçin, C., & Yalçıntaş Arslan, Ü.
(2024). Timing of Dose Reductions and Survival Outcomes in Metastatic Breast Cancer Patients Treated with Cyclin-Dependent Kinase 4/6 Inhibitors. Current Oncology, 31(12), 7426-7436.
https://doi.org/10.3390/curroncol31120548
